NEW YORK (GenomeWeb News) – The Allen Institute for Brain Science will perform in situ hybridization services on tissues for the ALS Therapy Development Institute (ALS TDI) to help identify cells linked to gene expression with the hope of developing treatments for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease, ALS TDI said today.
Under the agreement, the Allen institute will perform ISH for genes in the spinal cord that have been identified by ALS TDI scientists as having an association with the progression of the disease.
The collaborators hope to determine exactly where in the spinal cord the genes associated with the progression of ALS are active, according to Allen Institute COO Elaine Jones.
ALS TDI said its current data-mining program is identifying hundreds of therapeutic targets that need to be evaluated using in vivo techniques.
The ALS TDI researchers last year finished “an enormous database of transcriptome information” for a mouse model used in ALS research.
Cambridge, Mass.-based ALS TDI said that through a “multi-year funding partnership” with the Muscular Dystrophy Association and its Augie’s Quest Initiative, it has expanded its research program to include the largest genomics program for Lou Gehrig’s disease.
The Allen Institute for Brain Science is a Seattle-based non-profit that was established in 2003 with a $100 million seed donation from philanthropist and former Microsoft executive Paul Allen.